Kwang Hyun Ko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kwang Hyun Ko has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Chang-Il Kwon
Digestive Disease Center, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea
3 shared publications - Sung Hoon Choi
Division of Hepatobiliary and Pancreas, Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea
3 shared publications - Byung-Wook Kim
Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
2 shared publications - Gwang Ha Kim
Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea
2 shared publications - Hang Lak Lee
Department of Internal Medicine, Hanyang University Hospital, Seoul, Korea
2 shared publications - Hoon Jai Chun
Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 31 October 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (1) , 72-80
Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis
SUMMARY: Background: Tegoprazan is a novel potassium‐competitive acid blocker used to treat acid‐related disorders.Aim: To compare tegoprazan 25 mg with lansoprazole 15 mg as maintenance therapy in healed erosive oesophagitis (EE)Methods: In this phase 3, double‐blind, multi‐centre study, patients with endoscopically confirmed healed EE were randomised 1:1 to receive tegoprazan 25 mg or lansoprazole 15 mg once daily for up to 24 weeks. The primary efficacy endpoint was the endoscopic remission rate after 24 weeks. The secondary efficacy endpoint was the endoscopic remission rate after 12 weeks. Safety endpoints included adverse events, clinical laboratory results and serum gastrin and pepsinogen I/II levels.Results: We randomised patients to tegoprazan 25 mg (n = 174) or lansoprazole 15 mg (n = 177). Most had mild EE (Los Angeles (LA) grade A: 57.3%, LA grade B: 37.3%). The endoscopic remission rate after 24 weeks was 90.6% with tegoprazan and 89.5% with lansoprazole. Tegoprazan was not inferior to lansoprazole for maintaining endoscopic remission at 24 weeks and 12 weeks. In subgroup analysis, tegoprazan 25 mg showed no significant difference in maintenance rate according to LA grade (p = 0.47). The maintenance effect of tegoprazan was consistent in CYP2C19 extensive metabolisers (p = 0.76). Increases in serum gastrin were not higher in tegoprazan‐treated than lansoprazole‐treated patients.Conclusions: Tegoprazan 25 mg was non‐inferior to lansoprazole 15 mg in maintenance of healing of mild EE. In this study, tegoprazan had a similar safety profile to lansoprazole.
- 31 October 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (1) , 72-80
Open AccessRandomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis
SUMMARY: Background: Tegoprazan is a novel potassium‐competitive acid blocker used to treat acid‐related disorders.Aim: To compare tegoprazan 25 mg with lansoprazole 15 mg as maintenance therapy in healed erosive oesophagitis (EE)Methods: In this phase 3, double‐blind, multi‐centre study, patients with endoscopically confirmed healed EE were randomised 1:1 to receive tegoprazan 25 mg or lansoprazole 15 mg once daily for up to 24 weeks. The primary efficacy endpoint was the endoscopic remission rate after 24 weeks. The secondary efficacy endpoint was the endoscopic remission rate after 12 weeks. Safety endpoints included adverse events, clinical laboratory results and serum gastrin and pepsinogen I/II levels.Results: We randomised patients to tegoprazan 25 mg (n = 174) or lansoprazole 15 mg (n = 177). Most had mild EE (Los Angeles (LA) grade A: 57.3%, LA grade B: 37.3%). The endoscopic remission rate after 24 weeks was 90.6% with tegoprazan and 89.5% with lansoprazole. Tegoprazan was not inferior to lansoprazole for maintaining endoscopic remission at 24 weeks and 12 weeks. In subgroup analysis, tegoprazan 25 mg showed no significant difference in maintenance rate according to LA grade (p = 0.47). The maintenance effect of tegoprazan was consistent in CYP2C19 extensive metabolisers (p = 0.76). Increases in serum gastrin were not higher in tegoprazan‐treated than lansoprazole‐treated patients.Conclusions: Tegoprazan 25 mg was non‐inferior to lansoprazole 15 mg in maintenance of healing of mild EE. In this study, tegoprazan had a similar safety profile to lansoprazole.
- Top Cited PapersOpen Access
- 6 July 2022
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 16 (4) , 535-546
Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial
Yoon Jin Choi, Yong Chan Lee, Jung Mogg Kim, Jin Il Kim, Jeong Seop Moon, Yun Jeong Lim, Gwang Ho Baik, Byoung Kwan Son, Hang Lak Lee, Kyoung Oh Kim, Nayoung Kim, Kwang Hyun Ko, Hye-Kyung Jung, Ki-Nam Shim, Hoon Jai Chun, Byung-Wook Kim, Hyuk Lee, Jie-Hyun Kim, Hyunsoo Chung, Sang Gyun Kim, and Jae Young Jang. Gut and Liver 2022;16:535-46. https://doi.org/10.5009/gnl220055
- 6 July 2022
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 16 (4) , 535-546
Top Cited PapersOpen AccessTriple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial
Yoon Jin Choi, Yong Chan Lee, Jung Mogg Kim, Jin Il Kim, Jeong Seop Moon, Yun Jeong Lim, Gwang Ho Baik, Byoung Kwan Son, Hang Lak Lee, Kyoung Oh Kim, Nayoung Kim, Kwang Hyun Ko, Hye-Kyung Jung, Ki-Nam Shim, Hoon Jai Chun, Byung-Wook Kim, Hyuk Lee, Jie-Hyun Kim, Hyunsoo Chung, Sang Gyun Kim, and Jae Young Jang. Gut and Liver 2022;16:535-46. https://doi.org/10.5009/gnl220055
- Open Access
- 1 January 2022
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 102 (2) , 90-99
Preventive effect of biodegradable stents on biliary stricture and fibrosis after biliary anastomosis in a porcine model
Kwon CI, et al. Ann Surg Treat Res. 2022 Feb;102(2):90-99. https://doi.org/10.4174/astr.2022.102.2.90
- 1 January 2022
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 102 (2) , 90-99
Open AccessPreventive effect of biodegradable stents on biliary stricture and fibrosis after biliary anastomosis in a porcine model
Kwon CI, et al. Ann Surg Treat Res. 2022 Feb;102(2):90-99. https://doi.org/10.4174/astr.2022.102.2.90
- Open Access
- 15 November 2021
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 15 (6) , 841-850
Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study
Gwang Ha Kim, Hang Lak Lee, Moon Kyung Joo, Hong Jun Park, Sung Woo Jung, Ok-Jae Lee, Hyungkil Kim, Hoon Jai Chun, Soo Teik Lee, Ji Won Kim, Han Ho Jeon, Il-Kwun Chung, Hyun-Soo Kim, Dong Ho Lee, Kyoung-Oh Kim, Yun Jeong Lim, Seun-Ja Park, Soo-Jeong Cho, Byung-Wook Kim, Kwang Hyun Ko, Seong Woo Jeon, Jae Gyu Kim, In-Kyung Sung, Tae Nyeun Kim, Jae Kyu Sung, and Jong-Jae Park. Gut and Liver 2021;15:841-50. https://doi.org/10.5009/gnl20338
- 15 November 2021
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 15 (6) , 841-850
Open AccessEfficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study
Gwang Ha Kim, Hang Lak Lee, Moon Kyung Joo, Hong Jun Park, Sung Woo Jung, Ok-Jae Lee, Hyungkil Kim, Hoon Jai Chun, Soo Teik Lee, Ji Won Kim, Han Ho Jeon, Il-Kwun Chung, Hyun-Soo Kim, Dong Ho Lee, Kyoung-Oh Kim, Yun Jeong Lim, Seun-Ja Park, Soo-Jeong Cho, Byung-Wook Kim, Kwang Hyun Ko, Seong Woo Jeon, Jae Gyu Kim, In-Kyung Sung, Tae Nyeun Kim, Jae Kyu Sung, and Jong-Jae Park. Gut and Liver 2021;15:841-50. https://doi.org/10.5009/gnl20338
- Open Access
- 1 January 2020
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 99 (6) , 329-336
What is the better surgical treatment option for recurrent common bile duct stones?
Park CY, et al. Ann Surg Treat Res. 2020 Dec;99(6):329-336. https://doi.org/10.4174/astr.2020.99.6.329
- 1 January 2020
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 99 (6) , 329-336
Open AccessWhat is the better surgical treatment option for recurrent common bile duct stones?
Park CY, et al. Ann Surg Treat Res. 2020 Dec;99(6):329-336. https://doi.org/10.4174/astr.2020.99.6.329
- Open Access
- 1 January 2007
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 22 (1) , 1-7
The Usefulness of Angiotensin Converting Enzyme in the Differential Diagnosis of Crohn's Disease and Intestinal Tuberculosis
Kwon CI, et al. Korean J Intern Med. 2007 Mar;22(1):1-7. http://dx.doi.org/10.3904/kjim.2007.22.1.1
- 1 January 2007
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 22 (1) , 1-7
Open AccessThe Usefulness of Angiotensin Converting Enzyme in the Differential Diagnosis of Crohn's Disease and Intestinal Tuberculosis
Kwon CI, et al. Korean J Intern Med. 2007 Mar;22(1):1-7. http://dx.doi.org/10.3904/kjim.2007.22.1.1